![Jürgen Beck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Jürgen Beck
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
4
| Public Company | Pharmaceuticals: Major | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jürgen Beck tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Paion Deutschland GmbH
![]() Paion Deutschland GmbH BiotechnologyHealth Technology Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany. | Biotechnology | Chief Executive Officer Chief Executive Officer Director/Board Member | |
BIODEXA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chief Executive Officer | |
Talisker Pharma Ltd. | Chief Executive Officer | ||
BOTANIX PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
HERANTIS PHARMA OYJ | Pharmaceuticals: Major | Director/Board Member | |
Midatech Ltd.
![]() Midatech Ltd. BiotechnologyHealth Technology Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Jazz Pharmaceuticals UK Ltd.
![]() Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Pharmaceuticals: Major | President | |
Insense Ltd.
![]() Insense Ltd. BiotechnologyHealth Technology Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom. | Biotechnology | Director/Board Member | |
EUSA Pharma, Inc.
![]() EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Aplagon Oy
![]() Aplagon Oy Financial ConglomeratesFinance Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland. | Financial Conglomerates | Director/Board Member | |
ImevaX GmbH
![]() ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Biotechnology | Chief Executive Officer | |
Eusa Pharma Europe Ltd. | President | ||
Merckle GmbH
![]() Merckle GmbH Pharmaceuticals: MajorHealth Technology Merckle GmbH engages in the manufacture of pharmaceutical products. It offers specialty and generic medicines, as well as over-the-counter drugs. The firm also provides management services for the group. The company was founded in 1881 and is headquartered in Blaubeuren, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
gematik Gesellschaft für Telematikanwendungen der
![]() gematik Gesellschaft für Telematikanwendungen der Information Technology ServicesTechnology Services Gematik Gesellschaft für Telematikanwendungen der is a private company based in Berlin, Germany. The CEOs of the German company are Alexander Beyer, Markus Guilherme Dieken. The company is responsible for the telematics infrastructure (TI), which is the central platform for digital applications in German healthcare. | Information Technology Services | Chief Executive Officer | |
EUSA Pharma SAS
![]() EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Biotechnology | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
RWTH Aachen University | College/University | Doctorate Degree | |
ERGOMED | Miscellaneous Commercial Services | Director/Board Member | |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PAION, Inc.
![]() PAION, Inc. Pharmaceuticals: MajorHealth Technology Part of PAION AG, PAION, Inc. is a pharmaceutical manufacturing company. The company is based in Mahwah, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Metys Pharmaceuticals AG
![]() Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | Pharmaceuticals: Major | Director/Board Member | |
OXFORD BIOMEDICA PLC | Biotechnology | Chief Executive Officer | |
Cephalon, Inc.
![]() Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Director of Finance/CFO | |
Serono Laboratories (UK) Ltd. | Director of Finance/CFO | ||
Oxford Biomedica (UK) Ltd.
![]() Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Biotechnology | Director/Board Member | |
Virocell Biologics Ltd.
![]() Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Biotechnology | Chairman | |
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd.
![]() Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. develops ocular therapeutics and treatments for rare diseases. The private company is based in Beijing, CN. and has subsidiaries in the United States. The CEO of the Chinese company is Darren Mercer. | Miscellaneous Commercial Services | Director/Board Member | |
West Sussex Health Authority | Director/Board Member | ||
Lifegard Technologies | Director/Board Member | ||
Diabetology Ltd.
![]() Diabetology Ltd. Miscellaneous Commercial ServicesCommercial Services Diabetology Ltd. offers biopharmaceutical research and development services. It develops Capsulin and novel Axcess oral form of insulin for diabetics that incorporates absorption enhancers with unmodified bioactive in a convenient encapsulated form. The company was founded by Roger New and Glen Travers in 2002 and is headquartered in St. Helier, Jersey. | Miscellaneous Commercial Services | Director/Board Member | |
Vantia Ltd.
![]() Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Bayes Business School | College/University | Masters Business Admin | |
INTERMUNE INC | Biotechnology | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Regno Unito | 18 |
Germania | 8 |
Stati Uniti | 7 |
Finlandia | 4 |
Svizzera | 3 |
Settori
Health Technology | 25 |
Commercial Services | 5 |
Technology Services | 3 |
Consumer Services | 3 |
Finance | 2 |
Posizioni
Director/Board Member | 20 |
Chief Executive Officer | 13 |
Corporate Officer/Principal | 6 |
Founder | 2 |
Director of Finance/CFO | 2 |
Contatti più connessi
Insiders | |
---|---|
James Phillips | 24 |
John Dawson | 8 |
Wolfgang Söhngen | 6 |
Markus Guilherme Dieken | 6 |
- Borsa valori
- Insiders
- Jürgen Beck
- Connessioni Società